Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
Abstract Aim The wearable cardioverter‐defibrillator (WCD) is used for temporary protection from sudden cardiac death (SCD) in patients with newly diagnosed heart failure with reduced ejection fraction before considering an implantable cardioverter‐defibrillator (ICD). However, the prognostic signif...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13586 |
| _version_ | 1811247755043012608 |
|---|---|
| author | Johanna Mueller‐Leisse Johanna Brunn Christos Zormpas Stephan Hohmann Henrike Aenne Katrin Hillmann Jörg Eiringhaus Johann Bauersachs Christian Veltmann David Duncker |
| author_facet | Johanna Mueller‐Leisse Johanna Brunn Christos Zormpas Stephan Hohmann Henrike Aenne Katrin Hillmann Jörg Eiringhaus Johann Bauersachs Christian Veltmann David Duncker |
| author_sort | Johanna Mueller‐Leisse |
| collection | DOAJ |
| description | Abstract Aim The wearable cardioverter‐defibrillator (WCD) is used for temporary protection from sudden cardiac death (SCD) in patients with newly diagnosed heart failure with reduced ejection fraction before considering an implantable cardioverter‐defibrillator (ICD). However, the prognostic significance of the WCD remains controversial due to conflicting evidence. The aim of the present study was to evaluate prognosis of patients receiving life‐saving WCD shocks. Methods and results All patients receiving a WCD at Hannover Medical School for heart failure with reduced ejection fraction between 2012 and 2017 were included. Data were acquired at baseline, at 3 months and at last available follow‐up (FU). Three hundred and fifty‐three patients were included (69% male; age 56 ± 15 years; left ventricular ejection fraction 25 ± 8%). FU after the WCD was 2.8 ± 1.5 years with a maximum of 6.8 years. Daily WCD wear time was 22 ± 4 h. Fourteen patients (4%) received appropriate WCD shocks. Two patients (0.6%) died during the WCD period. Thirty patients (9%) died during extended FU. Mean estimated survival after the WCD was similar between patients with and without WCD shocks. Patients without an ICD recommendation after WCD prescription did not experience SCD during FU. Conclusions Patients with WCD shocks showed a favourable survival. Patients without an ICD recommendation after WCD prescription had no SCD during FU. These findings support the practice of careful risk stratification before considering an ICD and the use of the WCD for temporary protection from SCD. |
| first_indexed | 2024-04-12T15:15:14Z |
| format | Article |
| id | doaj.art-59af248927834aac9bc383d8d24e998c |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-04-12T15:15:14Z |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-59af248927834aac9bc383d8d24e998c2022-12-22T03:27:38ZengWileyESC Heart Failure2055-58222021-12-01865142514810.1002/ehf2.13586Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II studyJohanna Mueller‐Leisse0Johanna Brunn1Christos Zormpas2Stephan Hohmann3Henrike Aenne Katrin Hillmann4Jörg Eiringhaus5Johann Bauersachs6Christian Veltmann7David Duncker8Hannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyHannover Heart Rhythm Center, Department of Cardiology and Angiology Hannover Medical School Carl‐Neuberg‐Str. 1 Hannover 30625 GermanyAbstract Aim The wearable cardioverter‐defibrillator (WCD) is used for temporary protection from sudden cardiac death (SCD) in patients with newly diagnosed heart failure with reduced ejection fraction before considering an implantable cardioverter‐defibrillator (ICD). However, the prognostic significance of the WCD remains controversial due to conflicting evidence. The aim of the present study was to evaluate prognosis of patients receiving life‐saving WCD shocks. Methods and results All patients receiving a WCD at Hannover Medical School for heart failure with reduced ejection fraction between 2012 and 2017 were included. Data were acquired at baseline, at 3 months and at last available follow‐up (FU). Three hundred and fifty‐three patients were included (69% male; age 56 ± 15 years; left ventricular ejection fraction 25 ± 8%). FU after the WCD was 2.8 ± 1.5 years with a maximum of 6.8 years. Daily WCD wear time was 22 ± 4 h. Fourteen patients (4%) received appropriate WCD shocks. Two patients (0.6%) died during the WCD period. Thirty patients (9%) died during extended FU. Mean estimated survival after the WCD was similar between patients with and without WCD shocks. Patients without an ICD recommendation after WCD prescription did not experience SCD during FU. Conclusions Patients with WCD shocks showed a favourable survival. Patients without an ICD recommendation after WCD prescription had no SCD during FU. These findings support the practice of careful risk stratification before considering an ICD and the use of the WCD for temporary protection from SCD.https://doi.org/10.1002/ehf2.13586Heart failureSudden cardiac deathWearable cardioverter‐defibrillatorImplantable cardioverter‐defibrillator |
| spellingShingle | Johanna Mueller‐Leisse Johanna Brunn Christos Zormpas Stephan Hohmann Henrike Aenne Katrin Hillmann Jörg Eiringhaus Johann Bauersachs Christian Veltmann David Duncker Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study ESC Heart Failure Heart failure Sudden cardiac death Wearable cardioverter‐defibrillator Implantable cardioverter‐defibrillator |
| title | Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study |
| title_full | Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study |
| title_fullStr | Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study |
| title_full_unstemmed | Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study |
| title_short | Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study |
| title_sort | extended follow up after wearable cardioverter defibrillator period the prolong ii study |
| topic | Heart failure Sudden cardiac death Wearable cardioverter‐defibrillator Implantable cardioverter‐defibrillator |
| url | https://doi.org/10.1002/ehf2.13586 |
| work_keys_str_mv | AT johannamuellerleisse extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT johannabrunn extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT christoszormpas extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT stephanhohmann extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT henrikeaennekatrinhillmann extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT jorgeiringhaus extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT johannbauersachs extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT christianveltmann extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy AT davidduncker extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy |